The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes
Open accessAbstract
Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no international consensus on the definition of multidrug resistance exists, making direct comparison of the literature difficult. Inappropriate empirical therapy has been associated with increased mortality in P. aeruginosa infections; delays in starting appropriate therapy may contribute to increased length of hospital stay and persistence of infection. In addition, worse clinical outcomes may be associated with MDR infections owing to limited effective antimicrobial options. This article aims to summarize the contemporary literature on patient outcomes following infections caused by drug-resistant P. aeruginosa. The impact of antimicrobial therapy on patient outcomes, mortality and morbidity; and the economic impact of MDR P. aeruginosa infections will be examined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,499
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Multiple Mechanisms of Antimicrobial Resistance in Pseudomonas aeruginosa: Our Worst Nightmare?
Livermore, D. M. (2002) · Clinical Infectious Diseases · doi:10.1086/338782 · Cited by 1,453
Overview of Nosocomial Infections Caused by Gram-Negative Bacilli
Weinstein, R. A., Gaynes, R., Edwards, J. R., & System, N. N. I. S. (2005) · Clinical Infectious Diseases · doi:10.1086/432803 · Cited by 1,404
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Kumar, A., Ellis, P., Arabi, Y., Roberts, D., Light, B., Parrillo, J. E., Dodek, P., Wood, G., Kumar, A., Simon, D., et al. (2009) · Chest · doi:10.1378/chest.09-0087 · Cited by 1,187
Efflux-Mediated Drug Resistance in Bacteria: An Update
Li, X.-Z., & Nikaido, H. (2009) · Drugs · doi:10.2165/11317030-000000000-00000 · Cited by 966
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2004) · Drugs · doi:10.2165/00003495-200464020-00004 · Cited by 798
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabo, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 741
Roberts, R. R., Hota, B., Ahmad, I., Scott II, R. D., Foster, S. D., Abbasi, F., Schabowski, S., Kampe, L. M., Ciavarella, G. G., Supino, M., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/605630 · Cited by 705
Kang, C.-I., Kim, S.-H., Park, W. B., Lee, K.-D., Kim, H.-B., Kim, E.-C., Oh, M.-D., & Choe, K.-W. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.760-766.2005 · Cited by 692
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici, Shraga, Drucker, Konigsberger, Samra, Pitlik, & Pitlik (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00379.x · Cited by 685
Neuhauser, M. M., Weinstein, R. A., Rydman, R., Danziger, L. H., Karam, G., & Quinn, J. P. (2003) · JAMA · doi:10.1001/jama.289.7.885 · Cited by 678
The Impact of Antimicrobial Resistance on Health and Economic Outcomes
Eliopoulos, G. M., Cosgrove, S. E., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/375081 · Cited by 637
Multidrug-Resistant Pseudomonas aeruginosa : Risk Factors and Clinical Impact
Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., Cabili, S., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.43-48.2006 · Cited by 617
Efflux-mediated multiresistance in Gram-negative bacteria
Poole, K. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00763.x · Cited by 613
16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides
Doi, Y., & Arakawa, Y. (2007) · Clinical Infectious Diseases · doi:10.1086/518605 · Cited by 571
Kang, C., Kim, S., Kim, H., Park, S., Choe, Y., Oh, M., Kim, E., & Choe, K. (2003) · Clinical Infectious Diseases · doi:10.1086/377200 · Cited by 565
Micek, S. T., Lloyd, A. E., Ritchie, D. J., Reichley, R. M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1306-1311.2005 · Cited by 526
The biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472
Safdar, N., Handelsman, J., & Maki, D. G. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01108-9 · Cited by 417
Schwaber, M. J., Navon-Venezia, S., Kaye, K. S., Ben-Ami, R., Schwartz, D., & Carmeli, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1257-1262.2006 · Cited by 416
Falagas, M. E., Koletsi, P. K., & Bliziotis, I. A. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46747-0 · Cited by 399
Paul, M., Lador, A., Grozinsky-Glasberg, S., & Leibovici, L. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003344.pub3 · Cited by 377
Health and Economic Outcomes of Antibiotic Resistance in Pseudomonas aeruginosa
Carmeli, Y., Troillet, N., Karchmer, A. W., & Samore, M. H. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.10.1127 · Cited by 363
Mauldin, P. D., Salgado, C. D., Hansen, I. S., Durup, D. T., & Bosso, J. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01041-09 · Cited by 360
Systematic review of economic analyses of health care-associated infections
Stone, P. W., Braccia, D., & Larson, E. (2005) · American Journal of Infection Control · doi:10.1016/j.ajic.2005.04.246 · Cited by 338
Lodise, T. P., Patel, N., Kwa, A., Graves, J., Furuno, J. P., Graffunder, E., Lomaestro, B., & McGregor, J. C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00338-07 · Cited by 318
Gales, A. C., Jones, R. N., Turnidge, J., Rennie, R., & Ramphal, R. (2001) · Clinical Infectious Diseases · doi:10.1086/320186 · Cited by 309
Initial Low‐Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic
Cosgrove, S. E., Vigliani, G. A., Campion, M., Fowler, Jr., Abrutyn, E., Corey, G. R., Levine, D. P., Rupp, M. E., Chambers, H. F., Karchmer, A. W., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597031 · Cited by 309
Cosgrove, S. E., Kaye, K. S., Eliopoulous, G. M., & Carmeli, Y. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.2.185 · Cited by 299
Obritsch, M. D., Fish, D. N., MacLaren, R., & Jung, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4606-4610.2004 · Cited by 288
Vidal, F. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440170139015 · Cited by 275
Kollef, M. H. (2008) · Clinical Infectious Diseases · doi:10.1086/590061 · Cited by 248
Chatzinikolaou, I., Abi-Said, D., Bodey, G. P., Rolston, K. V. I., Tarrand, J. J., & Samonis, G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.501 · Cited by 238
Jalal, S., Ciofu, O., Høiby, N., Gotoh, N., & Wretlind, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.710-712.2000 · Cited by 236
Effectiveness of Combination Antimicrobial Therapy for Pseudomonas aeruginosa Bacteremia
Chamot, E., Boffi El Amari, E., Rohner, P., & Van Delden, C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2756-2764.2003 · Cited by 218
Galimand, M., Sabtcheva, S., Courvalin, P., & Lambert, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2949-2953.2005 · Cited by 209
Fitness of in vitro selected Pseudomonas aeruginosanalB and nfxB multidrug resistant mutants
Sanchez, P. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf185 · Cited by 209
Fluoroquinolone-Resistant Pseudomonas aeruginosa: Assessment of Risk Factors and Clinical Impact
Gasink, L. B., Fishman, N. O., Weiner, M. G., Nachamkin, I., Bilker, W. B., & Lautenbach, E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.029 · Cited by 206
Fraser, A., Paul, M., Almanasreh, N., Tacconelli, E., Frank, U., Cauda, R., Borok, S., Cohen, M., Andreassen, S., Nielsen, A. D., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.034 · Cited by 199
Epidemiology and Clinical Outcomes of Patients with Multiresistant Pseudomonas aeruginosa
Harris, A., Torres‐Viera, C., Venkataraman, L., DeGirolami, P., Samore, M., & Carmeli, Y. (1999) · Clinical Infectious Diseases · doi:10.1086/514760 · Cited by 194
Paramythiotou, E., Lucet, J., Timsit, J., Vanjak, D., Paugam‐Burtz, C., Trouillet, J., Belloc, S., Kassis, N., Karabinis, A., & Andremont, A. (2004) · Clinical Infectious Diseases · doi:10.1086/381550 · Cited by 177
Lautenbach, E., Weiner, M., Nachamkin, I., Bilker, W., Sheridan, A., & Fishman, N. (2006) · Infection Control & Hospital Epidemiology · doi:10.1086/507274 · Cited by 159
Tam, V. H., Chang, K., Abdelraouf, K., Brioso, C. G., Ameka, M., McCaskey, L. A., Weston, J. S., Caeiro, J., & Garey, K. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01446-09 · Cited by 147
Self-citationCao, B., Wang, H., Sun, H., Zhu, Y., & Chen, M. (2004) · Journal of Hospital Infection · doi:10.1016/j.jhin.2004.03.021 · Cited by 143
Cost of Gram-negative resistance*
Evans, H. L., Lefrak, S. N., Lyman, J. A., Smith, R. L., Chong, T. W., McElearney, S. T., Schulman, A. R., Hughes, M. G., Raymond, D. P., Pruett, T. L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000251496.61520.75 · Cited by 128
Li, X.-Z. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.6.885 · Cited by 124
Lautenbach, E., Synnestvedt, M. B., Weiner, M. G., Bilker, W. B., Vo, L., Schein, J. R., & Kim, M. (2009) · Infection Control and Hospital Epidemiology · doi:10.1086/649021 · Cited by 115
Risk factors for infections with multidrug‐resistant Pseudomonas aeruginosa in patients with cancer
Ohmagari, N., Hanna, H. A., Graviss, L. S., Hackett, B. C., Perego, C., González, V., Dvorak, T. L., Hogan, H., Hachem, R. Y., Rolston, K. V., et al. (2005) · Cancer · doi:10.1002/cncr.21115 · Cited by 107
Impact of Empiric Antibiotic Therapy on Outcomes in Patients with Pseudomonas aeruginosa Bacteremia
Osih, R. B., McGregor, J. C., Rich, S. E., Moore, A. C., Furuno, J. P., Perencevich, E. N., & Harris, A. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00901-06 · Cited by 101
Mutations Conferring Aminoglycoside and Spectinomycin Resistance in Borrelia burgdorferi
Criswell, D., Tobiason, V. L., Lodmell, J. S., & Samuels, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.445-452.2006 · Cited by 74
Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., LaRocco, M., Gentry, L. O., Lolans, K., Quinn, J. P., & Garey, K. W. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01674.x · Cited by 64
Self-citationBeta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for treating sepsis
Paul, M., Leibovici, L., Grozinsky‐Glasberg, S., Benuri‐Silbiger, I., & Soares‐Weiser, K. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003344 · Cited by 60
Combination Antimicrobial Treatment Versus Monotherapy: The Contribution of Meta-analyses
Paul, M., & Leibovici, L. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.01.004 · Cited by 53
Ramadhan, A. A., & Hegedus, E. M. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.024091 · Cited by 48
Yuan, Z., Ledesma, K. R., Singh, R., Hou, J., Prince, R. A., & Tam, V. H. (2010) · The Journal of Infectious Diseases · doi:10.1086/651024 · Cited by 30
Self-citationImpact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia
Tam, V. H., Chang, K., Schilling, A. N., LaRocco, M., Genty, L. O., & Garey, K. W. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.11.007 · Cited by 17
Self-citation
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Pseudomonas Aeruginosa: Resistance to the Max
Poole, K. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00065 · Cited by 948
Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria
Nikaido, H., & Pagès, J.-M. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00290.x · Cited by 769
Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface
Malhotra, S., Hayes, D., & Wozniak, D. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00138-18 · Cited by 515
Metadata
- Authors
- Hirsch, E. B., & Tam, V. H.
- Venue
- Expert Review of Pharmacoeconomics & Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2010-08
- Volume
- 10
- Issue
- 4
- Pages
- 441-451
- ISSN
- 1473-7167 (ISSN-L)
- 1744-8379
- OpenAlex
- W2033235589
- Cited by
- 406
- References
- 63
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.